Pharmadrug (TSE:PHRX) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
PharmaDrug is celebrating a significant advancement as its majority-owned subsidiary Sairiyo Therapeutics receives approval for a Phase 1 clinical trial in Australia. The trial will investigate the patented, reformulated oral drug PD-001, with potential applications in treating cancer and infectious diseases. This milestone follows years of research and will be instrumental in seeking FDA approval for further trials in the US.
For further insights into TSE:PHRX stock, check out TipRanks’ Stock Analysis page.